• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    3/26/24 9:05:52 AM ET
    $ABVC
    $BACK
    $BLRX
    $BLUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • Stoke Therapeutics (NASDAQ:STOK) stock increased by 80.2% to $11.71 during Tuesday's pre-market session. The market value of their outstanding shares is at $522.8 million. As per the press release, Q4 earnings came out yesterday.
    • OpGen (NASDAQ:OPGN) shares moved upwards by 77.6% to $0.84. The market value of their outstanding shares is at $8.4 million.
    • ABVC BioPharma (NASDAQ:ABVC) stock increased by 45.71% to $1.53. The market value of their outstanding shares is at $16.1 million.
    • Mesoblast (NASDAQ:MESO) shares moved upwards by 32.27% to $2.91. The market value of their outstanding shares is at $295.3 million.
    • Praxis Precision Medicine (NASDAQ:PRAX) shares increased by 21.38% to $61.3. The market value of their outstanding shares is at $811.5 million.
    • Sutro Biopharma (NASDAQ:STRO) stock moved upwards by 18.96% to $3.89. The company's market cap stands at $237.1 million. The company's, Q4 earnings came out yesterday.

    Losers

    • NeuBase Therapeutics (NASDAQ:NBSE) stock decreased by 55.0% to $0.45 during Tuesday's pre-market session. The company's market cap stands at $1.6 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares fell 14.49% to $1.24. The company's market cap stands at $1.8 million. The company's, Q4 earnings came out yesterday.
    • bluebird bio (NASDAQ:BLUE) shares fell 12.51% to $1.19. The company's market cap stands at $229.3 million. As per the press release, Q4 earnings came out today.
    • BioLine Rx (NASDAQ:BLRX) stock declined by 11.54% to $1.15. The market value of their outstanding shares is at $83.3 million. The company's, Q4 earnings came out today.
    • iSpecimen (NASDAQ:ISPC) stock fell 8.48% to $0.23. The market value of their outstanding shares is at $2.0 million.
    • IMAC Hldgs (NASDAQ:BACK) stock decreased by 8.27% to $2.22. The company's market cap stands at $2.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $BACK
    $BLRX
    $BLUE

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/24/2026$40.00Outperform
    Wolfe Research
    Praxis Precision Medicines Inc.
    $PRAX
    2/24/2026$500.00Outperform
    Wolfe Research
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Praxis Precision Medicines Inc.
    $PRAX
    2/2/2026$282.00Equal Weight
    Wells Fargo
    Sutro Biopharma Inc.
    $STRO
    1/20/2026$23.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Praxis Precision Medicines Inc.
    $PRAX
    12/15/2025$250.00 → $750.00Outperform
    Oppenheimer
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    More analyst ratings

    $ABVC
    $BACK
    $BLRX
    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

    CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC:OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name "CapForce" represents the "Force of Capital," symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their w

    2/27/26 5:30:32 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Ryoncil® Profits Underpinning Substantial Growth Pipeline

    NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026). FINANCIAL HIGHLIGHTS FOR H1 FY20261 Performance driven by successful commercial launch of Ryoncil® Total revenue of US$51.3 million (A$78.3 million),2 up from US$3.2 million.Successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd) generated gross sales of US$57.0 million and revenue of US$48.7 million after gross to net adjustment.Ryoncil® gross profit, excluding amortization, was US$44.2 million versus nil in

    2/26/26 7:42:54 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences. Conference Details: TD Cowen 46th Annual Health Care Conference Date: March 2-4, 2026Location: Boston, MA Leerink Partners Global Healthcare ConferenceDate: March 8-11, 2026 Location: Miami, FL The Citizens Life Sciences Conference Date: March 10-11, 2026Location: Miami, FL Barclays 28th Annual Global Healthcare ConferenceDate: March 10-12, 2026Location: Miami, FL We

    2/25/26 8:30:00 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $BACK
    $BLRX
    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Handley Michael K converted options into 8,824 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    2/20/26 4:19:42 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by CHIEF MEDICAL OFFICER Ticho Barry

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    2/19/26 4:25:56 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Smith Ian F

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    2/19/26 4:24:03 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BACK
    $BLRX
    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for APHEXDA issued to BIOLINERX, LTD.

    Submission status for BIOLINERX, LTD.'s drug APHEXDA (ORIG-1) with active ingredient MOTIXAFORTIDE has changed to 'Approval' on 09/08/2023. Application Category: NDA, Application Number: 217159, Application Classification: Type 1 - New Molecular Entity

    9/11/23 2:15:50 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $BACK
    $BLRX
    $BLUE
    SEC Filings

    View All

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    2/27/26 4:00:35 PM ET
    $BACK
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    2/27/26 9:18:59 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $BACK
    $BLRX
    $BLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Gerber Hans-Peter bought $13,607 worth of shares (17,000 units at $0.80), increasing direct ownership by 31% to 71,832 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    10/16/25 8:19:45 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO Chow Gregory K. bought $15,998 worth of shares (19,750 units at $0.81) (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    10/16/25 8:18:45 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Chung Jane bought $10,011 worth of shares (12,500 units at $0.80), increasing direct ownership by 11% to 122,850 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    10/16/25 8:17:03 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $BACK
    $BLRX
    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Stoke Therapeutics with a new price target

    Wolfe Research initiated coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:56:29 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Praxis Precision Medicines with a new price target

    Wolfe Research initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $500.00

    2/24/26 7:55:37 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BACK
    $BLRX
    $BLUE
    Leadership Updates

    Live Leadership Updates

    View All

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABVC
    $BACK
    $BLRX
    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

    SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

    11/14/24 7:54:45 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $BACK
    $BLRX
    $BLUE
    Financials

    Live finance-specific insights

    View All

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 - - Management to host conference call today, November 24th, at 8:30 am EST - TEL AVIV, Israel, Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update. "The clear highlight of the third quarter was our announc

    11/24/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

    Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2025 on Monday, November 24, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can

    11/18/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care